摘要
目的探讨非霍奇金淋巴瘤(NHL)患者血清乳酸脱氢酶(LDH)及β2-微球蛋白(β2-MG)水平检测与临床诊断、分期及治疗效果的关系。方法筛选32例初诊为NHL患者为观察组,其中Ⅰ期5例,Ⅱ期7例,Ⅲ期9例,Ⅳ期11例。以35名健康体检者为正常对照组。全部入组对象均采集清晨空腹静脉血检测LDH、β2-MG值。结果 (1)NHL血清LDH及β2-MG水平明显高于对照组(P<0.01);(2)Ⅲ+Ⅳ期患者血清LDH及β2-MG水平明显高于Ⅰ+Ⅱ期患者(P<0.01);(3)化疗2个疗程后,其血清LDH及β2-MG水平较治疗前明显降低(P<0.01)。结论血清LDH及β2-MG水平检测可作为NHL诊断、分期、疗效评估的参考指标。
Objective To study the relationship between the serum level of LDH,β2-MG and clinical diagnosis,stage and effectiveness of treatment in patients with non-Hodgkin lymphoma（NHL）.Methods The level of serum LDH and β2-MG in 32 patients with NHL（NHL group） and 35 healthy subjects（control group）were detected respectively.Results（1）The level of serum LDH and β2-MG in NHL group were obviously higher than those in the control group（P＆lt;0.01）;（2）The level of serum LDH and β2-MG in Ⅲ＋Ⅳstage were obviously higher than that in Ⅰ＋Ⅱ stage（P＆lt;0.01）;（3） After two cycles of chemotherapy,there was statistical difference between prechemotherapy and postchemotherapy（P＆lt;0.01）.Conclusion The levels of serum LDH and β2-MG can be taked as an reference index for diagnosis,classification,effectiveness of treatment in the patients with NHL.
出处
《中国临床新医学》
2013年第3期221-223,共3页
CHINESE JOURNAL OF NEW CLINICAL MEDICINE
关键词
非霍奇金淋巴瘤
乳酸脱氢酶
Β2-微球蛋白
Non-Hodgkin’s lymphoma（NHL）
Lactic dehydrogenese（LDH）
Beta-microglobulin（β2-MG）
